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Abstract
Purpose: The purpose of this study was to investigate the expression of autophagy-related proteins in relation to androgen
receptor (AR) status in estrogen receptor (ER)-negative breast cancers.
Methods: We extracted 334 ER-negative breast cancer samples to construct tissue microarrays (TMAs), which were
immunohistochemically stained for autophagy-related proteins (beclin-1, LC3A, LC3B, p62) and for AR and HER-2.
Results: There were 127 AR-positive cases and 207 AR-negative cases, and 140 HER-2-positive cases and 194 HER-2 negative
cases. The AR-negative group was associated with tumoral LC3A expression (P,0.001), while the AR-positive group was
associated with tumoral BNIP3 expression (P,0.001). Tumoral LC3A was most highly expressed in the AR-negative and HER-
2 negative group, while stromal LC3A showed the highest expression in the AR-negative and HER-2-positive group. Tumoral
BNIP3 and stromal BNIP3 were highest in the AR-positive and HER-2-negative group. In the AR-positive and HER-2-negative
group, stromal p62 positivity was an independent factor that was statistically significant in its association with shorter
disease-free survival (DFS) (Hazard ratio: 10.21, 95% CI: 1.130–92.31, P= 0.039). Shorter DFS was associated with tumoral
LC3A positivity (Hazard ratio: 10.28, 95% CI: 2.068–51.19, P= 0.004) in the AR-negative and HER-2-positive group.
Conclusion: In ER-negative breast cancers, AR status was associated with expression of different types of autophagy-related
proteins. Tumoral LC3A was most highly expressed in AR-negative breast cancers, while tumor BNIP3 was highest in AR-
positive breast cancers.
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Introduction
Autophagy is defined as the lysosomal degradation of cellular
components within cells. There are three types of autophagy:
microautophagy, chaperone-mediated autophagy and macroauto-
phagy, which is the most commonly employed type. Autophagy
removes dysfunctional or damaged cellular components while
recycling cellular components that can be re-used, thereby playing
an important homeostatic role within the cell [1–4]. Autophagy-
related proteins that are used as markers to evaluate activation
levels of autophagy include: beclin-1 [5–8], a protein known to
participate in the nucleation process; LC3A [9–11], a protein that
participates in the elongation process and thereby forms
autophagosomes; P62, a scaffolding protein that transfers
ubiquitinated protein to autophagosomes; and BNIP3, which
plays a central role in mitophagy, the autophagy process within
mitochondria. However, autophagy is not limited to normal cells;
it is also reported to play a significant role in cancer cells. In
general, the cancer cell adopts specialized metabolic processes
through angiogenesis and/or aerobic glycolysis in their usual harsh
hypoxic and nutrient-deficient environment. However, in partic-
ularly highly aggressive malignant tumors, where stresses are
higher for metabolic demand, these specialized metabolic path-
ways may not be sufficient, so some tumors may adopt an
alternative metabolic pathway of autophagy [12,13]. In such cases,
autophagy works to recycle cytoplasmic components to supply
extra energy to the cell. Therefore, the autophagy process should
be closely associated with metabolism in cancer progression and
survival.
The development and natural history of breast cancer is
significantly influenced by the status of steroidal hormones, such as
those of estrogen. It is common practice to evaluate the status of
estrogen receptor (ER) and progesterone receptor (PR) in order to
treat and prognosticate breast cancer. In addition to ER/PR,
androgen receptor (AR) is another steroidal hormone that
influences and is associated with breast cancers, but the
relationship is still not clearly understood. In general, androgen
receptors are expressed in 70% of all breast cancers [14], with
higher rates in apocrine and lobular types [15]. Previous studies
have revealed that ER negativity is associated with glycolysis-
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related proteins such as Glut-1, CAIX and MCT-4 [16,17].
Therefore, it has been suggested that ER-negative breast cancer
has a higher metabolic activity than ER-positive breast cancer.
Because the autophagy process should be closely associated with
metabolism in cancer progression and survival, it is expected that
autophagy activity is more elevated in ER-negative breast cancer
than in ER-positive breast cancer. However, AR status and its
association with autophagy-related proteins remain unexplored.
The purpose of this study was to investigate how autophagy-
related proteins are expressed in relation to AR status in ER-
negative breast cancers and to determine the corresponding
clinical implications.
Materials and Methods
Patient Selection and Clinicopathologic Evaluation
Formalin-fixed paraffin-embedded tissue samples of patients
diagnosed with invasive ductal carcinoma, no specific type, from
January 2005 to December 2012 at Severance Hospital were
included in this study. The study was approved by the Institutional
Review Board (IRB) of Severance Hospital. IRB board waived the
need for written informed consent. Those cases that had
undergone pre-operative chemotherapy were excluded. Informa-
tion on ER, AR and HER-2 status was collected from pathology
reports. A cut-off value of 1% or more positively stained nuclei was
used to define ER and AR positivity [18]. HER-2 staining was
analyzed according to the American Society of Clinical Oncology
(ASCO)/College of American Pathologists (CAP) guidelines using
the following categories: 0 = no immunostaining; 1+=weak
incomplete membranous staining, less than 10% of tumor cells;
2+= complete membranous staining, either uniform or weak in at
least 10% of tumor cells; and 3+=uniform intense membranous
staining in at least 30% of tumor cells [19]. HER-2 immuno-
staining was considered positive when strong (3+) membranous
staining was observed, whereas cases with 0 to 1+were regarded as
negative. The cases showing 2+ HER-2 expression were evaluated
for HER-2 amplification by fluorescent in situ hybridization
(FISH).
All cases were retrospectively reviewed by a breast pathologist
(Koo JS), in which histological evaluation was based on
hematoxylin and eosin (H&E)–stained slides. The histological
grade was assessed using the Nottingham grading system [20].
Tumor staging was based on the 7th American Joint Committee
on Cancer (AJCC) criteria. Disease-free survival (DFS) was
calculated from the date of the first curative surgery to the date
of the first loco-regional or systemic relapse, or death without any
type of relapse. Overall survival (OS) was estimated from the date
of the first curative operation to the date of the last follow-up or
death from any cause. Clinicopathologic parameters evaluated in
each breast cancer included patient age at initial diagnosis, lymph
node metastasis, tumor recurrence, distant metastasis, and patient
survival.
Tissue Microarray
After reviewing H&E–stained slides, the most suitable formalin-
fixed, paraffin-embedded (FFPE) tumor tissue samples were
retrospectively selected. The most representative tumor region
on the FFPE sample was then marked and a 3-mm tissue core
sample was extracted using a punch machine and planted onto a
665 recipient block. A total of 2 tissue cores were taken for all
samples in this TMA construction.
Immunohistochemistry
The antibodies used for immunohistochemistry in this study are
shown in Table 1. Briefly, FFPE blocks were sectioned at a
thickness of 3 um and then deparaffinized and rehydrated using
xylene and alcohol solutions, respectively. Sections were then
stained using the VentanaDiscoversy XT automated stainer
(Ventana Medical System, Tucson, AZ, USA). Antigen retrieval
was achieved by soaking sections in a CC1-buffered solution (Cell
Conditioning 1; citrate buffer Ph 6.0, Ventana Medical System).
The appropriate positive and negative controls were included
together with the study sample for staining.
Interpretation of Immunohistochemical Results
Interpretations of IHC stains were standardized as the
proportion of stained cells multiplied by the intensity of the
immunohistochemical staining. The proportion of stained cells
was scored with a system ranging from 0 to 2, defined as follows: 0
represented a negative result, 1 represented a section in which less
than 30% of cells were positively stained, and 2 represented a
section in which more than 30% of cells were positively stained.
Immunostaining intensity was scored with a system ranging from 0
to 3, defined as follows: 0 represented a negative result, 1
represented weak, 2 represented moderate, and 3 represented
strong. The number obtained after the multiplication of stained
cell proportion by immunostaining intensity resulted in the overall
interpretation score: 0–1 was defined as negative, 2–6 as positive
[21].
Statistical Analysis
Data were statistically processed using SPSS for Windows
version 12.0 (SPSS Inc., Chicago, IL). Student’s t test and Fisher’s
exact test were used for continuous and categorical variables,
respectively. To analyze data with multiple comparisons, a
corrected P-value with application of the Bonferroni method for
multiple comparisons was used. Statistical significance was
assumed when P,0.05. Kaplan-Meier survival curves and log-
rank statistics were employed to evaluate time to tumor metastasis
Table 1. Clone, dilution, and source of antibodies used.
Antibody Clone Dilution Source
Autophagy related
Beclin-1 Polyclonal 1:100 Abcam, Cambridge, UK
LC3A EP1528Y 1:100 Abcam, Cambridge, UK
LC3B Polyclonal 1:100 Abcam, Cambridge, UK
p62 SQSTM1 1:100 Abcam, Cambridge, UK
BNIP3 Ana40 1:100 Abcam, Cambridge, UK
doi:10.1371/journal.pone.0105666.t001
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Figure 1. Expression of autophagy-related proteins according to AR and HER-2 status in ER-negative breast cancer. Tumoral LC3A
expression was highest in the AR (–)/HER-2 (–) group, and lowest in the AR (+)/HER-2 (+) group. Stromal LC3A was highest in the AR (–)/HER-2 (+)
group, and lowest in the AR (–)/HER-2 (–) group. Tumoral BNIP3 and stromal BNIP3 had the highest expression in the AR (+)/HER-2 (–) group and
lowest in the AR (–)/HER-2 (–) group. Expression of Beclin-1, LC3B, and p62 is similar among 4 subgroups.
doi:10.1371/journal.pone.0105666.g001
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Figure 2. Correlation between clinicopathologic parameters and expression of autophagy-related proteins in ER-negative breast
cancer.
doi:10.1371/journal.pone.0105666.g002
Figure 3. Correlation between clinicopathologic parameters and expression of autophagy-related proteins in the AR (+)/HER-2 (+)
group.
doi:10.1371/journal.pone.0105666.g003
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and time to survival. Multivariate regression analysis was
performed using a Cox proportional hazards model.
Results
Basal Characteristics of Patients According to the AR and
HER-2 Status in ER-Negative Breast Cancer
There were 127 AR-positive cases, and 140 HER-2-positive
cases. After dividing samples into four groups based on AR and
HER-2 status, there were 53 cases in the AR (+)/HER-2 (–) group,
74 cases in the AR (+)/HER-2 (+) group, 66 cases in the AR (–)/
HER-2 (+) group and 141 cases in the AR (–)/HER-2 (–) group.
When ER negative cancer was divided into groups according to
AR and HER-2 status, these groups exhibited a noticeable
difference in age at diagnosis and Ki-67 expression levels. AR
negative group was associated with older age and higher Ki-67
LI(P=0.003, and P,0.001, respectively). While within the AR
negative group, HER-2positive group was shown to be associated
with older age at diagnosis and HER-2 negative group with higher
Ki-67 LI(P=0.030, and P=0.002, respectively, Table 2).
Expression of Autophagy-Related Proteins According to
the AR and HER-2 Status in ER-Negative Breast Cancer
Among autophagy-related proteins, LC3A, LC3B, BNIP3
exhibited cytoplasmic expression. In the case of beclin-1 and
p62 proteins, these showed cytoplasmic and nuclear expression.
Reports in the literature indicate that when these proteins
exhibited nuclear expression, they were unrelated with autophagy
activity. Therefore, we eliminated those with nuclear expression
from our data and only counted those with cytoplasmic expression
as positive [22,23].
For expression of autophagy-related proteins according to AR
and HER-2 status in ER-negative breast cancers, tumoral LC3A
expression was highest in the AR (–)/HER-2 (–) group, and lowest
in the AR (+)/HER-2 (+) group (P,0.001). Stromal LC3A was
highest in the AR (–)/HER-2 (+) group, and lowest in the AR (–)/
HER-2 (–) group (P,0.001). Tumoral BNIP3 and stromal BNIP3
had the highest expression in the AR (+)/HER-2 (–) group and
lowest in the AR (–)/HER-2 (–) group (P,0.001, and P=0.009,
respectively, Figure 1).
For expression of autophagy-related proteins according to AR
status, tumoral LC3A was expressed most highly in the AR-
negative group (P,0.001), while tumoral BNIP3 was most highly
expressed in the AR-positive group (P,0.001, and Table 3).
Correlation between Clinicopathologic Parameters and
Expression of Autophagy-Related Proteins in ER-Negative
Breast Cancer
Autophagy-related protein expression according to clinicopath-
ologic parameters was analyzed in ER-negative breast cancer
Figure 4. Correlation between clinicopathologic parameters and expression of autophagy-related proteins in the AR-negative
group.
doi:10.1371/journal.pone.0105666.g004
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(Figure 2). Tumoral LC3A positivity was significantly associated
with higher histologic grade (P,0.001), higher Ki-67 LI (P,
0.001), AR negativity (P,0.001), and HER-2 negativity (P,
0.001), while stromal LC3A positivity showed a significant
relationship with HER-2 positivity (P,0.001). Tumoral LC3B
positivity was associated with higher histologic grade (P=0.016),
while tumoral BNIP3 positivity was significantly associated with
AR positivity (P,0.001) and HER-2 positivity (P,0.001).
In each of the four groups defined by AR and HER-2 status, we
analyzed the autophagy-related protein expression according to
clinicopathologic parameters. The AR (+)/HER-2 (+) group was
the only group that showed a significant association between
tumoral p62 positive and higher histologic grade (P=0.032) as
well as higher T stage (P=0.032, Figure 3).
In each of the groups, autophagy-related protein expression
with clinicopathologic parameters was assessed according to AR
status (Figure 4). Within the AR-negative group, tumoral LC3A
positivity was associated with higher histologic grade (P=0.016),
higher Ki-67 LI (P=0.001), AR negativity (P,0.001) and HER-2
negativity (P,0.001). Stromal LC3A positivity was associated with
HER-2 positivity (P,0.001) and tumoral BNIP3 positivity was
associated with HER-2 positivity (P,0.001).
Impact of Expression of Autophagy-Related Proteins on
Prognosis
According to univariate analysis of autophagy-related protein
expression with prognosis, no factors were significantly associated
with prognosis (Table 4). However, amongst the four groups
divided based on AR and HER-2 status, the AR (+)/HER-2 (–)
group showed shorter disease-free survival (DFS) in association
with stromal p62 positivity (P=0.006), while in the AR (+)/HER-
Figure 5. Impact of expression of autophagy-related proteins on prognosis according AR and HER-2 status in ER-negative breast
cancer.
doi:10.1371/journal.pone.0105666.g005
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2 (+) group, shorter DFS was associated with tumoral beclin-1
negativity (P=0.029). In the AR (–)/HER-2 (+) group, shorter
DFS and shorter overall survival were significantly associated with
tumoral LC3A positivity (P,0.001 and P=0.013, respectively,
Figure 5).
Multivariate Cox analysis revealed that in the AR (+)/HER-2 (–)
group, stromal p62 positivity was an independent factor significantly
associated with shorter DFS (Hazard ratio: 10.21, 95% CI: 1.130–
92.31, P=0.039, Table 5), while in the AR (–)/HER-2 (+) group,
tumoral LC3A positivity was an independent factor significantly
associated with shorter DFS (Hazard ratio: 10.28, 95% CI: 2.068–
51.19, P=0.004, Table 6).
Discussion
In the current study, expression of autophagy-related proteins
according to AR status in ER-negative breast cancer was
evaluated. Tumoral LC3A expression was highest in AR-negative
breast cancer, while tumoral BNIP3 was highest in AR-positive
breast cancer. In previous studies on invasive breast cancers,
expression of autophagy-related proteins such as LC3A, LC3B,
and beclin-1 was shown to be associated with ER negativity and
PR negativity [24]. Therefore, it was suggested that hormone
receptor-negative breast cancers were more closely associated with
autophagy activity, and for ER-negative breast cancers, particu-
larly AR-negative breast cancers, there was an association with
increased autophagy activity. Although there are no studies that
have explored the relationship between AR and autophagy in
breast cancer, there have been studies of prostate cancer tumors,
which are most representative of AR-positive tumors. While there
are reports that AR positivity promotes autophagy in prostate
cancer [25], there are reports of AR positivity with lower levels of
autophagy activity [26,27]. The current study revealed that there
was an association between AR negativity and LC3A expression in
which was that of an inverse relationship. This inverse relationship
can be explained through an adapted interpretation of what has
been already reported in prostate cancer studies. One study
concluded that endoplasmic reticulum chaperone glucose-regulat-
ed protein 78/BiP(Grp 78/Bip) is upregulated by AR, which
ultimately results in autophagy inhibition [26]. Another study
demonstrated that AR increases p62 expression, which in turn
inhibits autophagy [28]. Regardless of whether AR promotes or
inhibits autophagy in prostate cancer, there is a consistent finding
among these different studies that AR does play a role in cancer
cell growth. Further in vitro cellular studies of AR and autophagy
in breast cancer are required.
Our study is unique because this is the first in literature to
analyze the relationship between BNIP3 and AR. Previous studies
have done so far as to observe an overexpression of BNIP3 in
Table 4. Univariate analysis by log-rank test of the impact of metabolism-related protein expression in estrogen receptor-negative
breast cancer on disease-free survival and overall survival times.
Disease-free survival (months) Overall survival (months)
Parameters 95% CI P-value 95% CI P-value
Beclin-1 (T) 0.295 0.917
Negative 114 (106–123) 124 (117–131)
Positive 97 (92–101) 119 (113–125)
LC3A (T) 0.596 0.314
Negative 117 (110–125) 123 (116–129)
Positive 111 (100–122) 129 (120–137)
LC3A (S) 0.537 0.796
Negative 117 (109–124) 125 (119–130)
Positive 75 (70–80) 76 (72–80)
LC3B (T) 0.325 0.432
Negative 114 (105–123) 121 (114–129)
Positive 116 (108–124) 121 (115–127)
p62 (T) 0.907 0.289
Negative 112 (99–125) 117 (106–128)
Positive 117 (111–124) 126 (120–131)
p62 (S) 0.850 0.616
Negative 118 (111–125) 126 (121–132)
Positive 91 (83–99) 111 (100–122)
BNIP3 (T) 0.750 n/a
Negative 117 (110–124) n/a
Positive 90 (83–97) n/a
BNIP3 (S) 0.570 n/a
Negative 117 (110–124) n/a
Positive 93 (84–102) n/a
doi:10.1371/journal.pone.0105666.t004
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breast cancers [29]. The relationship between BNIP3 and AR
expressions would be explained through the mechanism of
autocrine loop of tyrosine kinase receptor/phosphatidylinositol
39-kinase/protein kinase B. In a AR positive prostate cancer cell
study, androgen had activated this tyrosine kinase receptor/
phosphatidylinositol 39-kinase/protein kinase B which increases
HIF-1a and HIF-a regulated gene expression [30]. BNIP3
happens to be one such HIF-a regulated gene [31].
In the current study of breast cancers, BNIP3 was highly
expressed in the AR-positive group, which corresponded with a
previous report of a significant association between BNIP3
expression and AR in prostate cancers [32]. The proposed
mechanism for these findings is as follows; in prostate cancer,
androgen is bound to AR, which activates HIF-1a through a
cascade of several protein kinase systems, continuously increasing
expression of the HIF-1a-related gene, one of which is BNIP3.
BNIP3 increases mitophagy and prevents oxidative phosphoryla-
tion in mitochondria [33,34]. Therefore, metabolism of tumor
cells is shifted from mitochondrial oxidative phosphorylation to
oxidative glycolysis, known as the Warburg effect [35]. Although it
remains unclear if similar mechanisms are at work between AR
and BNIP3 in breast cancer, as shown with prostate cancer, this
study demonstrates that the AR-positive group has higher
expression of BNIP3 in ER-negative breast cancer, suggesting
possible causal mitochondrial dysfunction within the AR-positive
group in ER-negative breast cancer.
Within the AR-negative group, there was a significant difference
in LC3A and BNIP3 expression between the HER-2-positive and
HER-2-negative groups. However, in the AR-positive group, there
was no significant difference between HER-2-positive and HER-2-
negative groups in autophagy-related protein expression. The ER
(–)/AR (–)/HER-2 (+) group can be presumed to be mostly the
HER-2 type, and the ER (–)/AR (–)/HER-2 (–) group is thought
to be the basal-like/triple negative types. Because HER-2 type and
basal-like/triple negative type are both distinct clinicopathologic
entities [36,37], differences in autophagy activity according to
HER-2 status in the AR-negative group could be explained. The
ER-negative and AR-positive group could be classified as
molecular apocrine breast cancer (MABC) according to surrogate
immunohistochemical markers in this study. In the literature,
MABC is reportedly 20–50% HER-2 overexpressed/amplified
[38,39]. In the current study, 58.3% had HER-2 overexpression/
amplification that was similar to the reported value. Although
HER-2 status is an important biomarker in breast cancers, the
current study revealed that there is no difference in the expression
of autophagy-related proteins between the AR (+)/HER-2 (–)
group and AR (+)/HER-2 (+) group, which is compatible with
results from a previous study indicating that MABC does not
exhibit differences in tumor characteristics according to HER-2
status [38].
Our study observed cytoplasmic expression of LC3A, LC3B and
BNIP3 and nuclear expression in beclin-1 and p62. Previous
reports noted that different expression patterns of LC3A had
resulted in different biologic behaviors of tumors; in tumors with
diffuse cytoplasmic or perinuclear LC3A expression had an
association with ER and PR positivity, whereas those tumors with
stone-like pattern of LC3A expression was associated with ER and
PR negativity and a worse prognosis [10]. In the current study,
there were no cases with stone-like pattern expression of LC3A.
Instead, the majority exhibited cytoplasmic and/or perinuclear
pattern. This may be due to difference in the antibody used from
previous reports. However there are still other studies that support
the observation that according to the type of tumor there may be
no stone-like pattern expression of LC3A. All in all, LC3A seems
to be an area that merits much study [40,41]. In the case of p62
and beclin1, nuclear expression was observed in addition to
cytoplasmic expression. This finding is in agreement with previous
reports that observed both nuclear and cytoplasmic expression of
p62 [42,43]. This finding is attributed to the fact that p62 is a
major component of the nuclear pore complex that functions as a
nucleocytoplasmic transport thereby allowing it to exist both in
nucleic and cytoplasmic compartments [22]. Beclin1 is also known
to be expressed in both nucleic and cytoplasmic compartments
[23]. Although there is no study dealing with the nuclear
expression of beclin1, in one study on brain tumors, beclin1
tended to shift towards nucleic expression as the grade of the
tumor worsens. This observation signified that beclin1 protein
transports between both nucleic and cytoplasmic compartments,
but more importantly this shift in expression implied the loss of
becline1 gene function [23]. In summary, nucleic expression of
beclin1 would imply a suspension of its role in autophagy
regulation.
Although there was no association between autophagy-related
protein expression and breast cancer prognosis in ER-negative
breast cancer, in the AR (+)/HER-2 (–) group, stromal p62
positivity was an independent factor associated with shorter DFS,
while in the AR (–)/HER-2 (+) group, tumoral LC3A positivity
was an independent factor for shorter DFS. Previous studies have
revealed that LC3A expression in ovarian clear cell carcinoma
[44], non-small cell lung carcinoma [45], and colorectal adeno-
carcinoma [46] is associated with poor prognosis, providing a basis
for the claim that increased autophagy associates with poor
prognosis. With this in mind, the reason that LC3A was associated
with poor prognosis only in the AR (–)/HER-2 (+) group is a
question that requires further study. Also, it was stromal p62
expression that was associated with prognosis rather than tumoral
p62 expression. Expression of p62, LC3A, LC3B, and BNIP3 in
stromal cells in breast cancer was reported in a previous study
[24]. The association between stromal p62 expression and poor
prognosis may be explained by the reverse Warburg effect theory.
The reverse Warburg effect is a theory that proposes a metabolic
interaction between tumor cells and stromal cells in breast cancer,
where the reactive oxygen species produced from tumor cells result
in glycolysis, mitochondrial dysfunction, and increased autophagy
in stromal cells. In addition, the lactate produced from stromal cell
glycolysis is in turn utilized by the tumors in oxidative
phosphorylation to produce ATP [47–51]. Therefore, breast
cancers that produce energy by the reverse Warburg effect have an
advantage in tumor growth and maintenance. If the AR (+)/HER-
2 (–) group, in which stromal cells express p62, is presumed to
produce energy by the reverse Warburg effect, it may be then
associated with poor prognosis. The stromal cell that shows
increased autophagy activity is called the cancer-associated
fibroblast according to the reverse Warburg effect theory, and it
is characterized by caveolin-1 loss[49]. Caveolin-1 loss is reported
to occur in 5–40% of all breast cancers [52–54], and therefore
only a portion of breast cancers would be exhibiting the reverse
Warburg effect.
In conclusion, there was a significant difference in autophagy-
related protein expression according to AR status in ER-negative
breast cancer. Tumoral LC3A expression was higher in AR-
negative breast cancer, while tumoral BNIP3 was higher in AR-
positive breast cancer.
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